
|Articles|January 12, 2021
Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients
Author(s)OT Staff Reports
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
3
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
4
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
5























